Poseida’s Potential CAR T-cell Therapy Shows Positive Early Results in Phase 1 Multiple Myeloma Trial
News
Poseida Therapeutics’ CAR T-cell therapy candidate P-BCMA-101 is showing superior safety over alternatives and significant effectiveness in patients with relapsed or refractory multiple myeloma, according to early results of ... Read more